{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
BioCardia, Inc. Stock Plummets to New 52-Week Low of $1.00
BioCardia, Inc. has reached a new 52-week low of USD 1.00, reflecting its performance in a challenging market. With a market cap of USD 12 million, the company has a low debt-to-equity ratio of 0.30 and a high return on equity of 466.28%, despite being loss-making.
BioCardia, Inc. Stock Plummets to New 52-Week Low of $1.53
BioCardia, Inc. has reached a new 52-week low of USD 1.53, contrasting with its high of USD 3.25. With a market cap of USD 12 million, the company shows a low debt-to-equity ratio of 0.30 and a high return on equity of 466.28%, despite being unprofitable.
Is BioCardia, Inc. overvalued or undervalued?
As of August 9, 2023, BioCardia, Inc. is considered overvalued and has moved to a "does not qualify" valuation grade due to negative financial ratios and poor stock performance, with a year-to-date return of -7.34% compared to the S&P 500's 2.44%.
Is BioCardia, Inc. technically bullish or bearish?
As of May 15, 2025, BioCardia, Inc. is in a mildly bearish trend, driven by bearish weekly MACD and Bollinger Bands, despite some mixed signals from monthly indicators.
Who are in the management team of BioCardia, Inc.?
As of March 2022, the management team of BioCardia, Inc. includes Dr. Simon Stertzer (Independent Chairman), Dr. Peter Altman (CEO), Dr. Krisztina Zsebo, and several independent directors: Jim Allen, Andrew Blank, Fernando Fernandez, and Richard Krasno. They oversee the company's strategic direction and operations.
What does BioCardia, Inc. do?
BioCardia, Inc. is a clinical-stage regenerative medicine company focused on developing therapeutics for cardiovascular diseases, with a market cap of $10.93 million and a recent net profit of -$3 million. The company operates in the Pharmaceuticals & Biotechnology industry and has a debt equity ratio of 0.36.
How big is BioCardia, Inc.?
As of Jun 18, BioCardia, Inc. has a market capitalization of 10.93 million, with net sales of 0.00 million and a net profit of -8.40 million over the last four quarters. The company reported shareholder's funds of 0.84 million and total assets of 3.72 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
